David A. Siegel Nkarta, Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.27 - $10.82 $76,942 - $157,972	14,600 New	14,600 $86,000
Q4 2023 Feb 14, 2024	SELL	$1.31 - $6.6 $88,294 - $444,840	-67,400 Reduced 86.3%	10,700 $70,000
Q3 2023 Nov 14, 2023	SELL	$1.39 - $2.29 $4,865 - $8,015	-3,500 Reduced 4.29%	78,100 $108,000
Q2 2023 Aug 14, 2023	SELL	$2.19 - $5.17 $104,244 - $246,092	-47,600 Reduced 36.84%	81,600 $178,000
Q1 2023 May 15, 2023	SELL	$3.37 - $6.3 $200,515 - $374,850	-59,500 Reduced 31.53%	129,200 $458,000
Q4 2022 Feb 14, 2023	SELL	$5.14 - $14.35 $192,750 - $538,125	-37,500 Reduced 16.58%	188,700 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$12.27 - $18.39 $769,329 - $1.15 Million	62,700 Added 38.35%	226,200 $2.98 Million
Q2 2022 Aug 15, 2022	BUY	$7.77 - $19.44 $1.27 Million - $3.18 Million	163,500 New	163,500 $2.01 Million
Q1 2022 May 16, 2022	SELL	$8.66 - $14.99 $198,314 - $343,271	-22,900 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$12.79 - $26.88 $292,891 - $615,552	22,900 New	22,900 $352,000

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $119M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.